named programs · 3 · from sources
What they call their work
Chemoprevention Studies
Preclinical evaluation of natural compounds and dietary factors (e.g., vitamin D, calcium, Lycium barbarum) for cancer prevention.
Molecular Biomarkers of Cancer Risk
Develops cell culture and mouse models to study early molecular changes in colorectal and breast cancer.
Wnt Signaling Pathway Research
Investigates the role of Wnt signaling in breast and colon cancer development and identifies potential therapeutic targets.
activities · 5 groups
What they do
-
Biomedical Research and Innovation 1 activity
- Cancer researchConducts clinical and laboratory research on carcinogenesis, cancer prevention, and early detection, with a history spanning nearly eighty years. Research includes studies on breast, colorectal, lung, and cervical cancers, as well as the development of cell and animal models to investigate cancer risk and prevention.
-
-
Medical Professional Education & Training 1 activity
- Capacity building and professional education in cancer preventionTrains paramedical personnel in cancer detection through the CanScreen™ Program and provides ongoing education to primary care physicians via the PREVENTION e-newsletter series. Also repositioned the institute in 2009 to preserve its legacy and ensure institutional sustainability.
-
-
Medical Research & Education Dissemination 1 activity
- Development and dissemination of cancer screening guidelinesDevelops, updates, and promotes evidence-based guidelines for cancer screening and prevention practices, informed by recommendations from the National Cancer Institute (NCI), National Comprehensive Cancer Network (NCCN), and American Cancer Society (ACS).
-
-
Cancer Research Funding 1 activity
- Funding cancer prevention researchOperates as an independent nonprofit organization dedicated to funding cancer prevention research and promoting early detection.
-
-
Uncategorized 1 activity
- Direct clinical implementation of cancer screening innovationsIntroduced the Pap test into clinical practice in 1940 as the first medical facility in the U.S. to do so, and pioneered the use of sigmoidoscopy and stool slide tests for early detection of colon cancer. Also launched a specialized breast surveillance program for high-risk women and established the first National High-risk Registry for breast cancer.
-
financials · form 990 · fy2024
revenue
Total revenue$17K
Contributions & grants$1881%
Program service revenue$00%
Investment income$17K99%
Other revenue$0
expenses
Total expenses$268K
Program expenses91%
Admin / overhead9%
Fundraising0%
Salaries & benefits$0
Grants paid out$20K
Largest expense lineProfessional Fees
balance sheet
Total assets$597K
Cash$597K
Investments$0
Liabilities$11K
Net assets$586K
Liquid reserves26.7 mo
4 years on record · 2020–2024 · YoY revenue +15.3%
leadership · form 990 part vii · fy2024
Who runs it
paid leadership · 2
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| MICHAEL P OSBORNE | President | 10 | $60K |
| Merle K Barash | Trustee | 5 | $16K |
board members · 2
- Douglas C Anderson — Treasurer
- ELIZABETH WHITWORTH — Trustee
relationships · 28
Who they work with
- American Cancer Society Network — Uses ACS guidelines in developing and updating cancer screening and prevention recommendations.
- American Cancer Society Network — Uses ACS guidelines to develop and update cancer screening and prevention best practices.
- American Cancer Society Network — Uses American Cancer Society guidelines to develop and update cancer screening and prevention best practices.
- Beth Israel Medical Center Partner — Collaborated with Strang on early mammography screening studies in the 1960s.
- Cornell University Medical College Partner — Dr. Elise Strang L’Esperance was the first woman graduate from the Department of Pathology and later became Professor of Preventive Medicine.
- Dr. George Papanicolaou Partner — Collaborated on research into cytological changes in cervical cells for early cancer detection.
- Dr. May Edward Chinn Partner — Collaborated on cytological methods for early-stage cancer detection.
- Dr. Michael P. Osborne Partner — Collaborated with Merle K. Barash to reposition Strang in 2009 and secure its future as a nonprofit institution.
- Hereditary Breast Cancer Clinical Study Group Partner — Collaborated on multiple studies related to BRCA mutations and breast cancer risk.
- Memorial Hospital for Cancer and Allied Diseases Partner — Dr. Elise Strang L’Esperance worked with Dr. James Ewing at this institution during the early stages of her career.
- Memorial Sloan Kettering Cancer Center Partner — Former Chief, Head and Neck Service at Memorial Sloan Kettering Cancer Center is a consultant for STRANG CANCER PREVENTION INSTITUTE INC
- Memorial Sloan Kettering Cancer Center Partner — Merle K. Barash is affiliated with Memorial Sloan Kettering Cancer Center as a board member of STRANG CANCER PREVENTION INSTITUTE INC.
- Mount Sinai Health System Partner — Elizabeth Whitworth is affiliated with Mount Sinai Health System as a board member of STRANG CANCER PREVENTION INSTITUTE INC.
- National Cancer Institute Government — Uses NCI guidelines in developing and updating cancer screening and prevention recommendations.
- National Cancer Institute Government — Uses National Cancer Institute guidelines to develop and update cancer screening and prevention best practices.
- National Cancer Institute Network — Uses NCI guidelines to develop and update cancer screening and prevention best practices.
- National Comprehensive Cancer Network Network — Uses NCCN guidelines to develop and update cancer screening and prevention best practices.
- National Consortium of Cancer Centers Network Network — Uses NCCCN guidelines in developing and updating cancer screening and prevention recommendations.
- National Consortium of Cancer Centers Network Network — Uses National Consortium of Cancer Centers Network guidelines to develop and update cancer screening and prevention best practices.
- New York Hospital-Cornell Medical Center Partner — Affiliated with Strang in 1990.
- New York Infirmary Partner — Hosted the founding of the Kate Depew Strang Clinic.
- New York Presbyterian Hospital Partner — Clinical Director at New York Presbyterian Hospital is a consultant for STRANG CANCER PREVENTION INSTITUTE INC
- New York Presbyterian Hospital / Weill Cornell Medical Center Partner — Hosted Dr. Gaynor as Director of Medical Oncology at its Center for Integrative Oncology.
- RCA Partner — Collaborated with Strang to design a computer system for risk factor analysis.
- The Rockefeller University Partner — Hosts the relocated Strang Cancer Research Laboratory and the Strang Cancer Biology Laboratory.
- University of Maryland Partner — Professor of the Practice at University of Maryland is a consultant for STRANG CANCER PREVENTION INSTITUTE INC
- Weill Cornell Medicine Partner — Professor at Weill Cornell Medicine is a consultant for STRANG CANCER PREVENTION INSTITUTE INC
- Weill Medical College of Cornell University Partner — Appointed Dr. Gaynor as Clinical Assistant Professor of Medicine.
strategies · 5
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Early Detection and Research Translationmethodology: early_detection_and_researchBy advancing scientific research and translating findings into clinical practice, we prevent cancer through earlier diagnosis and intervention, because early-stage detection significantly improves treatment outcomes and reduces mortality.
- Evidence-Based Guideline Developmentmethodology: evidence_based_guideline_developmentBy synthesizing recommendations from national organizations, we produce standardized, evidence-informed cancer screening and prevention guidelines that improve consistency and quality of care, because adherence to expert consensus increases early detection rates and reduces unnecessary procedures.
- Evidence-Informed Nutritional Sciencemethodology: evidence_informed_nutritionBy grounding nutritional recommendations in population data and laboratory research, we support cancer prevention and treatment because biologically plausible dietary interventions can modulate cancer risk pathways.
- Integrative Oncology and Holistic Supportmethodology: integrative_oncologyBy integrating mind-body-spirit therapies with conventional treatment, we support holistic healing and improve patient resilience, because addressing psychological and lifestyle factors enhances treatment adherence and overall well-being.
- Personalized Risk Assessment and Multidisciplinary Surveillancemethodology: personalized_risk_surveillanceBy using algorithmic and biological risk modeling to identify high-risk individuals and coordinating multidisciplinary care, we improve cancer prevention outcomes because tailored surveillance and shared decision-making increase adherence and early intervention.